Tumor markers in lung cancer and neuroendocrine tumors: a complete guide for patients (CYFRA 21-1, NSE, ProGRP, Chromogranin A)

Have you done tests and seen elevated values such as “CYFRA 21-1”, “NSE” or “ProGRP” and got scared? Or are you a smoker and wondering what these “pulmonary” markers mean? First of all, remember a basic principle valid in 2026: tumor markers are not used for screening in healthy people and, taken individually, cannot diagnose cancer. Their true value appears in choosing treatment and monitoring the evolution of the disease. This guide explains, in a way that everyone can understand, what each pulmonary and neuroendocrine marker means and how it guides medical decisions.

1. Why does the “type” of lung cancer matter?

A fundamental aspect that few patients know: lung cancer is not a single disease. There are four major histopathological categories , and each has its “preferred” marker:

• Lung adenocarcinoma – the main marker is CEA
• Squamous cell carcinoma (epidermoid) – the main marker is CYFRA 21-1
• Small cell lung cancer (SCLC) – the main markers are NSE and ProGRP
• Pulmonary neuroendocrine tumors (carcinoids, LCNEC) – the main markers are Chromogranin A and NSE

Why is this important? Because each type responds differently to treatment, and the right marker helps the doctor “track” the disease correctly. Choosing the wrong marker would provide unreliable information.

2. CYFRA 21-1: marker of lung squamous cell carcinoma

CYFRA 21-1 is a fragment of cytokeratin 19 released by damaged epithelial cells and is the preferred marker for squamous cell carcinoma of the lung (NSCLC-SCC) . The normal value is below 3.3 ng/mL.

Here is how the values are interpreted:

CYFRA value 21-1	Possible meaning
<3.3 ng/mL	Normal
3.3–10 ng/mL	Benign lung diseases (inflammations)
>10 ng/mL	Advanced squamous cell lung carcinoma, poorer prognosis

The most important use of CYFRA 21-1 is monitoring: a decrease in the value under treatment indicates a good therapeutic response, while an increase signals disease progression. An increased CYFRA 21-1 at diagnosis is usually associated with a poorer prognosis.

3. NSE (Neuron-Specific Enolase): small cell cancer marker

NSE is an isoenzyme expressed in neuroendocrine cells and is the key marker for small cell lung cancer (SCLC) and other neuroendocrine tumors. The normal value is below 12.5 ng/mL.

Interpretation of values:

• 12.5–25 ng/mL – non-malignant neuronal lesions
• >25 ng/mL – small cell lung carcinoma, neuroblastoma; indicates advanced disease

NSE is elevated in 60–70% of patients with SCLC at diagnosis and is particularly useful for monitoring this aggressive type of cancer. A decrease in NSE indicates response to treatment, and persistence of elevated values suggests resistance.

Beware of an important pitfall: NSE can be falsely elevated in cases of hemolysis (destruction of red blood cells in the test tube), in smokers, and in neurodegenerative diseases. Therefore, correct sample collection is essential.

4. ProGRP: the most specific marker for SCLC

ProGRP (pro-gastrin-releasing peptide) is a sensitive and specific marker for small cell lung cancer , often preferred over NSE precisely because of its greater specificity. The normal value is below 50 pg/mL.

An elevated value (>50 pg/mL) indicates disease spread or recurrence. ProGRP is elevated in 60–90% of patients with SCLC, making it a very valuable monitoring tool. In practice, ProGRP and NSE are often used together for more accurate follow-up of this type of cancer.

5. Chromogranin A: marker of neuroendocrine tumors

Chromogranin A (CgA) is a protein secreted by neuroendocrine cells and serves as a general marker of neuroendocrine tumors (NETs) , regardless of their location – including lung (carcinoid) tumors. The normal value is below 100 ng/mL.

Interpretation of values:

• <100 ng/mL – normal; an active neuroendocrine tumor is unlikely
• 100–500 ng/mL – suggestive of a neuroendocrine tumor; requires imaging confirmation
• >1,000 ng/mL – significant tumor volume, associated with poorer prognosis

A key, lesser-known detail: Chromogranin A can be falsely elevated in patients taking antacid medications (proton pump inhibitors, such as omeprazole). Ideally, these medications should be discontinued about a week before the test, if possible. Other benign causes include atrophic gastritis, renal failure, and hypertension.

6. Markers of “hormonally active” neuroendocrine tumors

Some neuroendocrine tumors produce excess hormones, causing specific syndromes. In these cases, doctors measure special markers:

• Serotonin and urinary 5-HIAA (serotonin metabolite): elevated in carcinoid syndrome (flushing, diarrhea). A 5-HIAA value above 20 mg/24h is suggestive. Caution: foods rich in serotonin (bananas, tomatoes, pineapple, chocolate, nuts) should be avoided 48–72h before collection, in order not to falsify the result.
• Gastrin : elevated in gastrinoma (Zollinger-Ellison syndrome), a value above 1,000 pg/mL being diagnostic.
• Insulin and C-peptide : useful for diagnosing insulinoma, which causes recurrent hypoglycemia.
• Metanephrines : increased in pheochromocytoma (adrenal tumor), which causes hypertension, headaches, and palpitations.

7. Three golden rules for interpretation

1. Markers are not used for screening in healthy, asymptomatic smokers; they complement imaging (CT, PET) and biopsy, not replace it.
2. The trend over time (increase or decrease in repeated measurements) is much more important than a single isolated value.
3. Correct collection matters: hemolysis falsifies NSE, and antacids falsify Chromogranin A.

🫁 Pulmonary subtype	🎯 Main marker	📊 Normal value	🔎 Growth meaning
Adenocarcinoma	THE	<3.4 (non-smokers) / <4.5 (smokers) ng/mL	Progression, relapse
Squamous cell carcinoma	CYFRA 21-1	<3.3 ng/mL	Advanced disease, poor prognosis
Small cell carcinoma (SCLC)	NSE + ProGRP	NSE <12.5 ng/mL; ProGRP <50 pg/mL	Expansion, recurrence
Neuroendocrine tumors	Chromogranin A	<100 ng/mL	Active tumor mass

How Artificial Intelligence helps you correctly interpret pulmonary markers

As you have seen, lung cancer hides four different subtypes, each with its own marker, thresholds and pitfalls (hemolysis, antacid medication, serotonin-rich foods). Manually correlating all these variables with international guidelines is difficult, and treatment protocols are updated from one month to the next.

Oncoexpertai platform comes in . Unlike a simple reading of the analyses, our advanced Artificial Intelligence algorithms instantly scan your entire marker profile (CYFRA 21-1, NSE, ProGRP, Chromogranin A) and correlate it with thousands of clinical studies and international oncology guidelines updated in real time (NCCN / ESMO). The technology does not replace the doctor, but gives him the certainty that the proposed treatment regimen is the most suitable for your specific profile.

---

Disclaimer: The information in this article is for informational and educational purposes only. It is not a substitute for the consultation, diagnosis, or treatment provided by a qualified medical professional. For any decision regarding your health, always consult a medical professional.

Bibliography

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. NCCN Guidelines®. 2026.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. NCCN Guidelines®. 2026.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. NCCN Guidelines®. 2026.
4. Hendriks LE, Kerr KM, Menis J, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2023;34(4):358–376. doi: 10.1016/j.annonc.2022.12.013
5. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology. 2022;17(3):362–387. doi: 10.1016/j.jtho.2021.11.003
6. Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2021;32(7):839–853. doi: 10.1016/j.annonc.2021.03.207
7. Baudin E, Caplin M, Garcia-Carbonero R, et al. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2021;32(4):439–451. doi: 10.1016/j.annonc.2021.01.003

Dr. Onisim Florin Senior Medical Oncologist | Founder of OncoExpertAI

.